When injected into mice with retinal disease, the special retinal blood cells integrated into the damaged tissue to ...

Life Biosciences has received FDA clearance to begin a first-in-human Phase 1 clinical trial of ER-100, a gene therapy ...

Successful Type B RDEP Meeting confirms FDA alignment on pivotal Phase 3 study designFDA indicates Opus Genetics may submit a BLA based on ...

Quantified preferences favored higher lesion growth rate reduction (10%→50% at 18 months) as the primary driver across all ...

Belite Bio, Inc (NASDAQ: BLTE) ('Belite Bio®” or the 'Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have ...

Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the Company will present on its innovative ...

REGENXBIO Inc., a biotechnology company on a mission to improve lives through the curative potential of gene therapy, announced the first patient has been dosed in the phase IIb/III NAAVIGATE clinical ...

Blindness itself might become, at least in certain cases, partially reversible. This potential future stems from one of the ...

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing "off the shelf" allogeneic cell therapies for serious medical conditions, today ...

A retinal implant invented by a Stanford scientist is restoring limited vision to people with advanced macular degeneration, helping some read and recognize faces again.

The retina, as a highly specialized and metabolically demanding neural tissue, is vulnerable to a wide spectrum of debilitating disorders — including ...

4FRONT-1, the first 4D-150 wet AMD phase 3 trial, is being conducted in North America in treatment-naïve patients with an ...